Ayurveda research translated into plain English
CCRAS clinical trials, AYUSH policy updates, and WHO traditional medicine news — covered for consumers, not practitioners.
FSSAI Ashwagandha Leaves Advisory: What's Actually Happening (June 2026 Update)
FSSAI's April 2026 advisory tried to prohibit ashwagandha leaves in supplements. Eight companies took it to Karnataka High Court. On May 12 the HC issued a stay. The matter is back in court on June 8. Here is what's actually going on.
How to Read a Clinical Trial About Ayurvedic Herbs (Without a Medical Degree)
RCT, p-value, double-blind, sample size, effect size — the vocabulary that lets you evaluate any herb claim. A patient walkthrough using real Ayurvedic trials as examples.
What Is CCRAS — and Why Their Research Matters for Every Ayurveda User in India
CCRAS is the Indian government's clinical-research arm for Ayurveda. Most consumers have never heard of it. Here's a plain-English explainer of what they do, what they've published, and why it matters.
WHO and AYUSH MoU 2025: What It Actually Means for Ayurveda Research
In May 2025, India's Ministry of AYUSH signed a US$3 million MoU with WHO on traditional medicine. I read the official documents — here is what it actually does, what it doesn't, and what consumers should watch for.